News Brief: Eli Lilly’s Next-Gen Obesity Drug Shows Record Weight Loss
Summary
Eli Lilly announced strong late-stage trial results for its experimental obesity drug, retatrutide. The drug demonstrated unprecedented weight loss and significantly reduced knee arthritis pain, marking a major advancement in obesity treatment.
Key Points
- Record Weight Loss: Patients lost an average of 23.7% of body weight (28.7% for those who completed treatment) over 68 weeks on the highest dose.
- Pain Reduction: The drug reduced knee osteoarthritis pain by up to 62.6% on average; over 1 in 8 patients became pain-free.
- Novel Mechanism: Retatrutide, dubbed “triple G,” mimics three gut hormones (GLP-1, GIP, glucagon), unlike current drugs that target one or two.
- Strategic Focus: Lilly positions it for severe obesity (BMI ≥35). 84% of trial participants had a BMI above this threshold.
- Side Effects: Common issues included nausea (43%), diarrhea (33%), and vomiting (21%). Discontinuation rate was 18% on the highest dose, partly due to “perceived excessive weight loss.”
- Market Context: This data strengthens Lilly’s lead against rival Novo Nordisk in the booming obesity drug market, estimated to reach ~$100B by the 2030s.
- Next Steps: Results from seven additional Phase 3 trials are expected by the end of 2026.
新闻简报：礼来新一代减肥药在后期试验中显示卓越减重效果
摘要
礼来公司公布了其实验性减肥药retatrutide的强劲后期试验结果。该药物展现出前所未有的减重效果，并显著减轻膝关节关节炎疼痛，标志着肥胖症治疗领域的重大进展。
关键要点
- 创纪录的减重效果：使用最高剂量的患者在68周内平均减重23.7%（完成治疗的患者平均减重28.7%）。
- 疼痛减轻：该药物将膝骨关节炎疼痛平均减轻高达62.6%；超过八分之一的患者在试验结束时疼痛完全消失。
- 新颖的作用机制：Retatrutide被称为”三重G”药物，它模拟三种肠道激素（GLP-1、GIP和胰高血糖素），而现有药物仅针对一种或两种。
- 战略定位：礼来将其定位用于治疗严重肥胖（BMI≥35）。试验中84%的参与者BMI超过此阈值。
- 副作用：常见问题包括恶心（43%）、腹泻（33%）和呕吐（21%）。最高剂量的停药率为18%，部分原因是”感知体重减轻过多”。
- 市场背景：此数据巩固了礼来在蓬勃发展的减肥药市场中相对于竞争对手诺和诺德的领先地位，该市场预计到2030年代价值约1000亿美元。
- 后续步骤：另外七项三期试验的结果预计在2026年底前公布。
Original Article Link: https://www.cnbc.com/2025/12/11/eli-lillys-weight-loss-drug-retatrutide-clears-first-late-stage-study.html